BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • Wednesday
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEGlobeNewsWire • 10/21/26
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and GrowthGlobeNewsWire • 10/05/26
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/31/26
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a BetZacks Investment Research • 08/28/26
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Zacks Investment Research • 08/12/26
Implied Volatility Surging for BioCryst Pharmaceuticals Stock OptionsZacks Investment Research • 08/11/26
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/05/26